2019
Genetically diverse Plasmodium falciparum infections, within-host competition and symptomatic malaria in humans
Sondo P, Derra K, Lefevre T, Diallo-Nakanabo S, Tarnagda Z, Zampa O, Kazienga A, Valea I, Sorgho H, Ouedraogo J, Guiguemde T, Tinto H. Genetically diverse Plasmodium falciparum infections, within-host competition and symptomatic malaria in humans. Scientific Reports 2019, 9: 127. PMID: 30644435, PMCID: PMC6333925, DOI: 10.1038/s41598-018-36493-y.Peer-Reviewed Original ResearchConceptsParasite densityMalaria symptomsHemoglobin levelsP. falciparum genetic diversityMixed infectionsMAD20 allelic familyMono-infected individualsLower hemoglobin levelsPlasmodium falciparum infectionAllelic familiesLow parasite densitiesP. falciparum isolatesMixed strain infectionsFC27 allelesSymptomatic malariaOlder patientsFalciparum infectionYounger patientsPharmacovigilance studyFalciparum isolatesHigh parasitaemiaP. falciparumPolymorphic antigensPatientsInfection
2015
Ex vivo anti-malarial drug susceptibility of Plasmodium falciparum isolates from pregnant women in an area of highly seasonal transmission in Burkina Faso
Tahita M, Tinto H, Yarga S, Kazienga A, Traore/Coulibaly M, Valea I, Van Overmeir C, Rosanas-Urgell A, Ouedraogo J, Guiguemde R, van Geertruyden J, Erhart A, D’Alessandro U. Ex vivo anti-malarial drug susceptibility of Plasmodium falciparum isolates from pregnant women in an area of highly seasonal transmission in Burkina Faso. Malaria Journal 2015, 14: 251. PMID: 26088768, PMCID: PMC4474342, DOI: 10.1186/s12936-015-0769-1.Peer-Reviewed Original ResearchConceptsPregnant womenAnti-malarial drugsDrug sensitivity profilesParasite densityAnti-malarial drug susceptibilityDifferent drug sensitivity profilesUncomplicated Plasmodium falciparum malariaTreatment Efficacy TrialInfected pregnant womenArtemisinin-based combinationsPlasmodium falciparum malariaChloroquine-resistant isolatesHistidine-rich protein-2 assayPlasmodium falciparum isolatesGeometric mean IC50Low parasite densitiesP. falciparum parasitesTreatment of malariaFalciparum malariaRecurrent infectionsMean IC50Efficacy trialsFalciparum isolatesMethodsThe studyResistant parasites
2013
Anti-Pfs25 Human Plasma Reduces Transmission of Plasmodium falciparum Isolates That Have Diverse Genetic Backgrounds
Da D, Dixit S, Sattabonkot J, Mu J, Abate L, Ramineni B, Ouedraogo J, MacDonald N, Fay M, Su X, Cohuet A, Wu Y. Anti-Pfs25 Human Plasma Reduces Transmission of Plasmodium falciparum Isolates That Have Diverse Genetic Backgrounds. Infection And Immunity 2013, 81: 1984-1989. PMID: 23509152, PMCID: PMC3676035, DOI: 10.1128/iai.00016-13.Peer-Reviewed Original ResearchConceptsPhase 1 trialParasite isolatesMalaria transmission-blocking vaccineTransmission-reducing activityTransmission-blocking activityPlasmodium falciparum isolatesTransmission-blocking vaccinesPlasmodium falciparum parasitesLimited sequence polymorphismPfs25 antibodiesMontanide ISA51Immune plasmaNonimmune controlsRecombinant Pfs25Falciparum isolatesPfs25 geneFalciparum parasitesGenetic backgroundPatientsBurkina FasoPfs25VaccineTrialsNucleotide polymorphismsIsolates